AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE
AgNovos Bioscience announces that more than 150 patients have been enrolled in the RESTORE randomized, controlled trial of AGN1 LOEP.
Keep up to date on AgNovos events and related news
AgNovos Healthcare participated in WCO in Paris from April 4th - 7th, 2019
Once again, AgNovos Healthcare has joined with ESCEO to support the work of emerging bone health researchers.
AgNovos and ESCEO support young investigators at the “BREAKFAST EVENT” on Saturday April 06, 2019 from 08.00 - 09.00
AgNovos Healthcare will participate in WCO in Paris from April 4th - 7th, 2019 exhibiting the CE-marked OSSURE LOEP kit and host the ESCEO – AGNOVOS YOUNG INVESTIGATOR AWARD “BREAKFAST EVENT”
AgNovos Healthcare is proud to partner again with ESCEO to provide grants to young investigators at the WCO in Paris.
Current pharmaceutical therapies can reduce hip fractures by up to 50%, but compliance to treatment is low and therapies take up to 18 months to reduce risk. Thus, alternative or complementary approaches to reduce the risk of hip fracture are needed.